Ron Melling, CPA, is a partner in Crowe’s Audit and Assurance group and leads the firm’s Life Sciences audit practice. He serves as audit partner to domestic and international privately held and private equity–backed companies, PCAOB engagements, and publicly traded organizations. Ron brings deep industry expertise across Crowe’s life sciences subsectors, including biotechnology and pharmaceuticals; medical devices, MedTech and durable medical equipment; CDMO, CRO, diagnostics, and laboratory services; and specialty pharmacy and nutraceuticals. He has served in Crowe’s national office advising on complex technical accounting matters and has extensive international experience working with foreign subsidiaries and professional service providers throughout Asia and Europe.
Tom Shoemaker, CPA, is a partner in the life sciences audit and assurance group at Crowe. He specializes in IPO offerings, secondary offerings, reverse mergers, SEC comment letters, and periodic SEC reporting requirements. Tom has more than 25 years of experience providing services related to life sciences working in the clinical stage through commercialization. He has a deep understanding of the technical accounting complexities associated with debt and equity financings, stock-based compensation and revenue recognition, and other topics.
Michael Taglieri, CFA, is a managing director in Crowe’s advisory group and member of the valuation services practice. Michael specializes in life science and technology industries, providing valuation advisory services to clients spanning from pre-revenue start-ups to late-stage, middle market companies for a variety of purposes including financial reporting, management planning, mergers and acquisitions, tax and regulatory compliance, restructuring and reorganization, and corporate strategy. His experience includes valuing businesses and business interests, financial instruments including equity, fixed income, and complex derivative securities, and intangible assets.
Valuing early-stage life sciences companies can be complex. Because product development can take several years and be capital intensive, obtaining an accurate valuation is essential to align management’s, the shareholders’, and current and potential investors’ understanding of estimated value.